Skip to content
ASBESTOSIS CANCER CENTER

Asbestosis Cancer Center

asbestosiscancer.center

Menu
  • asbestosiscancer news
  • Treatment
  • Asbestosis Treatmeant
  • Tipes of Cancer
  • About us
    • Terms and Conditions
    • DMCA
    • Contact
    • Privacy Policy
    • DMCA
Menu

Exciting Developments in the HER2+ Breast Cancer Treatment Landscape – Cancer Network

Posted on May 19, 2022 by Asbestosis Cancer Center





© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Treatment Options for Early-Stage HER2+ Breast Cancer – Episode 7

Sarah M. Tolaney, MD, MPH, highlights recent and investigative treatments for HER2+ breast cancer that excite her and provides some clinical pearls for community oncologists.

Sarah M. Tolaney, MD, MPH: We’ve seen many new agents get approval in the last 2 years, which has dramatically changed outcomes for our metastatic, HER2 [human epidermal growth factor receptor 2]–positive patients. We’ve seen approval for trastuzumab deruxtecan [Enhertu] based on data from DESTINY-Breast01, which had shown unprecedented activity and pretreated HER2+ disease with a 60% response and an almost a 20-month progression-free survival [PFS]. We’ve seen data from DESTINY-Breast03 [DBO3] suggesting a PFS that wasn’t reached by central review but was it about 25 months with T-DXd [trastuzumab deruxtecan] compared with a little over 6 months with TDM-1 [trastuzumab emtansine]. It had a hazard ratio rate of 0.28, which is something I’ve never seen before in a registration study. T-DXd [trastuzumab deruxtecan] seems very different from any agent we’ve had for HER2+ cancers, and it’s changing the paradigm of our treatment approaches. In my mind, it should be a second-line standard after THP [docetaxel, trastuzumab, pertuzumab] based on data from DBO3.
We also have unique data from HER2CLIMB, suggesting that if you had tucatinib [TUKYSA] to capecitabine [Xeloda] and trastuzumab [Herceptin], you improve not only PFS but also OS [overall survival]. This is true even in patients with active brain metastases, where there was a 9-month improvement in overall survival from adding tucatinib to capecitabine and trastuzumab in patients with active brain metastases. This was the first registration-randomized trial to show a survival benefit from therapy and patients with HER2+ brain metastases. It’s a totally new finding, which thankfully is changing outcomes for our patients with brain metastases.
We touched on some data looking at margetuximab [Margenza], a new agent, and a novel monoclonal antibody that seems to perform better than trastuzumab in metastatic HER2+ disease. We also have approval for neratinib [Nerlynx] in combination with capecitabine and pretreated HER2+ breast cancer. There are so many treatment options, but it does bring up questions about optimal ways to sequence all these drugs. It needs to be done on an individual level, factoring in whether someone has brain metastases when you’re making these treatment decisions. Certainly, we’re also thinking about performance status ability to comply with oral therapies or get into an infusion. A lot of other things have to be factored in with these decisions, but there are so many options, all highly effective treatment approaches.
For early stage patients, it’s critical to use preoperative therapy as much as you can because it’s critical to understand the response to therapy. That allows you to adapt your adjuvant approach, which can change treatment outcomes. This is critical, particularly in stage II and III patients. But we’ve made such headway in improving outcomes for HER2+ patients by introducing more very potent HER2-directed therapies, such as adding pertuzumab [Perjeta] to trastuzumab and using TDM-1 [trastuzumab emtansine] in the residual disease setting. We’re improving efficacy, but we’re still using quite a bit of chemotherapy. It raises the question of how we can de-escalate therapy further for these patients. Thinking about clinical trial options for your early stage patients is really important to help tailor therapy and individualize a treatment approach. It will help us do better in the long run, where we can hopefully maintain the outstanding efficacy that we achieve but also reduce toxicity in our patients.
Transcript edited for clarity.
Related Content:

See also  Non-Small Cell Lung Cancer: X-Ray Procedure, Info, and Risks - Healthline

source

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent Posts

  • NYSDOH study: Cancer cluster in Northport-East Northport deemed not unusual – News 12 Bronx
  • Cancer Challenge hosts dinner, auction fundraiser – KNWA
  • New study suggests cancer spreads more rapidly depending on time of day – WISH TV Indianapolis, IN
  • Bristol Myers must face $6.4 bln lawsuit over delayed cancer drug – Reuters
  • Doctor told her sex was painful because of her age. It turned out to be ovarian cancer – Yahoo News

Recent Comments

  1. IvyBer on Gynecologic Cancer Studies: What to Look for at ASCO 2022 – Medscape
  2. hotshot bald cop on A solution to asbestos waste?
  • NYSDOH study: Cancer cluster in Northport-East Northport deemed not unusual – News 12 Bronx
  • Cancer Challenge hosts dinner, auction fundraiser – KNWA
  • New study suggests cancer spreads more rapidly depending on time of day – WISH TV Indianapolis, IN
  • Bristol Myers must face $6.4 bln lawsuit over delayed cancer drug – Reuters
  • Doctor told her sex was painful because of her age. It turned out to be ovarian cancer – Yahoo News
  • Asbestosis Treatmeant
  • asbestosiscancer news
  • Tipes of Cancer
  • Treatment

Info

  • Aviso Legal
  • Contact
  • Personalizar Cookies
  • Política de Cookies
  • Política de Privacidad
  • DMCA
  • Terms and Conditions
  • NYSDOH study: Cancer cluster in Northport-East Northport deemed not unusual – News 12 Bronx
  • Cancer Challenge hosts dinner, auction fundraiser – KNWA
  • New study suggests cancer spreads more rapidly depending on time of day – WISH TV Indianapolis, IN
  • Bristol Myers must face $6.4 bln lawsuit over delayed cancer drug – Reuters
  • Doctor told her sex was painful because of her age. It turned out to be ovarian cancer – Yahoo News

Signs of Asbestos Exposure in the HomeASBESTOSIS CANCER CENTER

➡️ Much of the asbestos was found in insulation for homes, schools, large buildings, boilers and furnaces. It’s easy to determine if you’re feeling as tremors. However signs of asbestos exposure in the home

Signs of Asbestos ExposureASBESTOSIS CANCER CENTER

➡️ Signs of Asbestos Exposure Asbestos has been used for more than 3,000 years. It was discovered in 4,500 B.C., and it became a popular building material in the 19th century, when it became widely available and inexpensive

©2022 Asbestosis Cancer Center | Built using WordPress and Responsive Blogily theme by Superb
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT